Miconazole Inhibitors
1 drugsAbout Miconazole
Miconazole is an antifungal drug target relevant for treating fungal infections. It is the active ingredient in at least one FDA-approved drug, highlighting its clinical significance.
Pharmacological modulation of Miconazole is achievable and therapeutically beneficial, as evidenced by the approved drug VUSION. There is currently no genetic evidence directly linking Miconazole to specific diseases in this dataset.
Miconazole is targeted by one FDA-approved drug, VUSION (Viatris), a small molecule. The therapeutic area associated with Miconazole-targeting drugs is classified as 'Other', related to its antifungal properties.
Top Miconazole Drugs
Viatris is the only company with an approved drug targeting Miconazole.
Low competition suggests easier market entry, but also indicates potential challenges in the target space.
Miconazole Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Miconazole, using small molecule modality.
The modality landscape suggests an opportunity to explore other modalities like antibodies or peptides.
Miconazole Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Miconazole. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Miconazole Drug Approval Timeline (2006 - 2006)
The first and most recent drug approval for Miconazole was VUSION in 2006.
The lack of recent approvals indicates potential saturation or challenges in developing new Miconazole-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Miconazole. A trial counts if an approved drug acting on Miconazole is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.